Full notification fileGeneral informationNotification NumberB/ES/08/46Member State to which the notification was sentSpainDate of acknowledgement from the Member State Competent Authority05/07/2008Title of the ProjectA Multicenter, Double Blind, Placebo controlled, Randomized study of TroVax® vs.
Placebo in the First Line treatment of Patients with Metastatic Colorectal Cancer receiving
chemo-based therapy – EFC10528.Proposed period of release:01/10/2008 to 30/09/2012Name of the Institute(s) or Company(ies)Sanofi-Aventis Recherche et Développement, 1, Avenue Pierre Brossolette
3. Is the same GMO release planned elsewhere in the Community?Yes: Belgium; Germany; France; United Kingdom; Italy; Netherlands; Czech Republic; Hungary; Poland; Has the same GMO been notified elsewhere by the same notifier?YesIf yes, notification number(s): GMO characterizationGMO is a:DNA VirusIdentity of the GMO:Poxviridae, VacciniaInformation relating to the recipient or parental organisms from wich the GMO is derived
European Commission administrative informationConsent given by the Member State Competent Authority:Not known